Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
1. TXG reported Q4 EPS loss of $(0.40), missing estimates. 2. Sales decreased 10% year-over-year but beat expectations at $165.02 million. 3. Gross margin rose to 67% due to favorable product mix changes. 4. Guidance for FY 2025 sales is lower than consensus at $610-$630 million. 5. Analysts hold mixed ratings, with two downgrades and one maintained Buy.